- The partnership is a critical step in the scale-up of CUTISS’s first-in-class automated platform for manufacturing personalized skin tissue.
- It enables the transition from engineering development to industrial-grade production, supporting commercial readiness.
- It directly supports CUTISS’s mission to bring denovoSkin™
— a personalized, bioengineered human skin graft — to market at scale, and to unlock the platform’s potential for other applications in regenerative medicine.
The collaboration brings industrial validation
to CUTISS’s proprietary automation platform, and will enable production at scale for clinical and future commercial deployment.